Galectin Therapeutics to Present at Upcoming Conferences
NORCROSS, Ga., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company’s president, chief executive officer and chief medical officer will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.
The BIO CEO presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
About BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. It has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to its investment banking activity. http://www.sourcegrp.com/
Jack Callicutt, Chief Financial Officer
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.